Please ensure Javascript is enabled for purposes of website accessibility

The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing as Much as 30%

By Sean Williams - Oct 26, 2017 at 5:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Insys' shareholders suffer through another Subsys-related beatdown, but is an end in sight?

What happened

Shares of Insys Therapeutics (INSY), a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy. One whammy was the arrest of the company's founder; another was negative commentary from President Trump regarding opioids in general.

So what

As very quick background: Insys' troubled lead drug Subsys, a synthetic opioid, has seen its sales slashed in half over the past two years, following allegations and lawsuits that management and its marketing team knowingly and willingly marketed the sublingual spray (approved to treat breakthrough cancer pain) for off-label indications. Some allegations suggest that up to 80% of Subsys' sales were for off-label uses. Insys has already been sued by the attorneys general of Massachusetts and New Jersey; it recently settled with Massachusetts for $500,000.

A closeup of a gavel in front of a judge's chair in a courtroom

Image source: Getty Images.

Today, Wall Street found out that the billionaire founder of Insys Therapeutics, John Kapoor, who still owns a majority stake in the company and was CEO as recently as January 2017, was arrested. He's been charged with engaging in conspiracies to commit racketeering, mail fraud, and wire fraud, based on the federal indictment filed in a Boston court. The charges, which Kapoor's attorney has denied, suggest that Kapoor and a handful of other executives devised a scheme to pay speaker fees and bribes to medical practitioners in return for prescribing Subsys to non-cancer patients. This was also a means to defraud insurers, according to the documents filed in Boston.

Adding insult to injury, President Trump also directed the Department of Health and Human Services (HHS) to declare the opioid crisis a public-health emergency. While the move might be short of a full-on emergency declaration from the president, it sets the wheels in motion for the HHS and regulatory bodies to limit access to opioid medicines. According to the American Society of Addiction Medicine, 20,101 people died in 2015 from prescription opioid-related overdoses.

Now what

What a mess.

The big issue with the arrest of Insys' founder, along with another former CEO, Michael Babich, is that it further clouds the near-term outlook for Insys. Subsys currently accounts for a majority of its sales, and the ongoing PR surrounding the company's marketing of this drug is liable to lead to weaker sales. Additionally, with other lawsuits potentially in the works, Insys could be subject to financial penalties and sales restrictions for its lead drug. In the very near term, it's quite likely that quarterly losses are going to steepen.

A cannabis leaf drawn between the hands of a doctor

Image source: Getty Images.

The only real saviors here are Insys' burgeoning portfolio and pipeline beyond Subsys. In August the company launched its oral dronabinol solution, Syndros, as a treatment for chemotherapy-induced nausea and vomiting (CINV), along with anorexia associated with AIDS. This synthetic version of tetrahydrocannabinol (THC) is entering a crowded CINV market, but it's a first-of-its-kind approved medicine, meaning it has a decent shot at $200 million or more in peak annual sales. Between Syndros and its recently filed new drug application for a sublingual buprenorphine spray -- assuming approval for the latter -- Insys could completely replace Subsys' sales in perhaps two or three years' time.

It's tough to see how things get better anytime soon for the company. But if it can manage to stabilize Subsys sales, even if those are well below $100 million annually, Insys could turn out to be a bargain for investors looking for a high-risk, high-reward stock.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

INSYS Therapeutics Stock Quote
INSYS Therapeutics
INSY

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.